Return to Trial Database

GYN06-106

A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer

Status

Study Completed

Cancer Type(s)

Study Contact

Publications

A Phase II, Open-Label, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer

Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis

Trial Locations

All sites in which the trial GYN06-106 being conducted in.

No data was found